Regeneron Pharmaceuticals, Inc. $REGN Holdings Increased by Illinois Municipal Retirement Fund

Illinois Municipal Retirement Fund raised its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 3.9% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 31,884 shares of the biopharmaceutical company’s stock after purchasing an additional 1,209 shares during the quarter. Illinois Municipal Retirement Fund’s holdings in Regeneron Pharmaceuticals were worth $24,177,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Western Wealth Management LLC purchased a new stake in shares of Regeneron Pharmaceuticals in the 1st quarter worth about $26,000. Armstrong Advisory Group Inc. boosted its stake in shares of Regeneron Pharmaceuticals by 466.7% during the 3rd quarter. Armstrong Advisory Group Inc. now owns 34 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 28 shares in the last quarter. Mowery & Schoenfeld Wealth Management LLC bought a new stake in shares of Regeneron Pharmaceuticals during the 2nd quarter valued at about $29,000. Trust Co. of Vermont purchased a new position in shares of Regeneron Pharmaceuticals during the second quarter valued at about $29,000. Finally, Fiduciary Financial Advisors purchased a new position in shares of Regeneron Pharmaceuticals during the second quarter valued at about $29,000. 83.31% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

REGN has been the subject of several research reports. JPMorgan Chase & Co. increased their target price on Regeneron Pharmaceuticals from $950.00 to $1,050.00 and gave the stock an “overweight” rating in a research report on Friday, October 30th. Argus raised Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $850.00 price objective for the company in a research report on Thursday, October 1st. Raymond James Financial raised their price objective on Regeneron Pharmaceuticals from $902.00 to $911.00 and gave the company an “outperform” rating in a research report on Friday, July 31st. Morgan Stanley boosted their target price on shares of Regeneron Pharmaceuticals from $779.00 to $855.00 and gave the company an “equal weight” rating in a report on Monday, November 2nd. Finally, Zacks Research raised shares of Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Monday, September 28th. One research analyst has rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and nine have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $898.97.

Regeneron Pharmaceuticals Stock Performance

NASDAQ:REGN opened at $916.06 on Wednesday. The stock has a 50-day simple moving average of $809.24 and a two-hundred day simple moving average of $744.46. Regeneron Pharmaceuticals, Inc. has a 52-week low of $591.52 and a 52-week high of $991.73. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.35. The firm has a market capitalization of $94.77 billion, a PE ratio of 19.26, a P/E/G ratio of 1.22 and a beta of 0.10.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Friday, October 30th. The biopharmaceutical company reported $20.07 EPS for the quarter, topping analysts’ consensus estimates of $16.51 by $3.56. Regeneron Pharmaceuticals had a return on equity of 16.01% and a net margin of 28.51%. The business had revenue of $5.12 billion during the quarter, compared to analysts’ expectations of $4.58 billion. During the same quarter in the prior year, the business posted $11.83 earnings per share. The business’s quarterly revenue was up 36.3% on a year-over-year basis. Analysts forecast that Regeneron Pharmaceuticals, Inc. will post 58.26 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, December 3rd. Investors of record on Friday, November 20th will be paid a dividend of $0.94 per share. The ex-dividend date is Friday, November 20th. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.4%. Regeneron Pharmaceuticals’s payout ratio is 8.30%.

Key Regeneron Pharmaceuticals News

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Regeneron reported promising first-in-human results for CIDEBsiRNA, an investigational treatment being developed with Alnylam for metabolic-dysfunction-associated steatotic liver disease (MASLD). A single dose rapidly normalized liver fat and improved liver-injury markers in patients. The early results could strengthen the program’s prospects, though further study is needed. Alnylam Collaborator Regeneron Advances CIDEBsiRNA with Promising First-in-Human Results in Patients with MASLD
• Neutral Sentiment: Soleo Health was selected as a specialty-pharmacy partner for Pasatru, Regeneron’s recently approved treatment for the rare disorder FOP. The partnership may help facilitate access, but the report provided no sales or uptake figures. Soleo Health Selected as a Specialty Pharmacy Partner for Pasatru
• Neutral Sentiment: A comparison of Regeneron and Amgen highlighted Regeneron’s lack of net debt and faster growth, but it was an investor-oriented analysis, not a new company announcement. Amgen vs. Regeneron: Higher Dividends Now or Bigger Growth Later?
• Neutral Sentiment: A short-interest entry describes a significant increase but reports total short interest of zero shares, making the data internally inconsistent and not a reliable directional signal.

Insider Buying and Selling

In other Regeneron Pharmaceuticals news, Director Kathryn Guarini sold 400 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Friday, October 30th. The shares were sold at an average price of $900.00, for a total transaction of $360,000.00. Following the transaction, the director owned 603 shares of the company’s stock, valued at $542,700. The trade was a 39.88% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Christine A. Poon sold 7,830 shares of the company’s stock in a transaction that occurred on Monday, November 2nd. The stock was sold at an average price of $969.09, for a total transaction of $7,587,974.70. Following the completion of the transaction, the director owned 5,219 shares of the company’s stock, valued at approximately $5,057,680.71. The trade was a 60.00% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 27,028 shares of company stock worth $25,025,950 in the last ninety days. Corporate insiders own 6.97% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc. is a biotechnology company that discovers, develops, manufactures and commercializes medicines for serious diseases. Its research and product portfolio spans areas including eye disease, allergic and inflammatory conditions, cancer, cardiovascular and metabolic disorders, infectious diseases and rare conditions. The company’s medicines include EYLEA for certain eye diseases, Dupixent for inflammatory conditions and Libtayo for cancer. Regeneron also develops and markets treatments with pharmaceutical partners, including Sanofi, and its products reach patients in the United States and international markets through its own operations and collaborations.